Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Takeda Pharmaceutical Ltd ADR
(NY:
TAK
)
13.77
+0.10 (+0.73%)
Official Closing Price
Updated: 7:00 PM EDT, Jul 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Takeda Pharmaceutical Ltd ADR
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
Takeda's Dengue Vaccine Candidate Under FDA Priority Review
November 23, 2022
Via
Benzinga
Takeda’s Biologics License Application (BLA) for Dengue Vaccine Candidate (TAK-003) Granted Priority Review by U.S. Food and Drug Administration
November 22, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Gamma Delta T Cell Therapy Market Could Reach $4 Billion As Biotechs Race To Get Breakthrough Cancer Treatment Approved
November 22, 2022
This year, the World Health Organization (WHO) announced that cancer has become the leading cause of death worldwide, with the latest data showing that nearly 10 million deaths in 2020 were the result...
Via
Benzinga
Why Puma Biotechnology's Shares Jumped 20% on Monday
November 21, 2022
It may have benefited from positive news about another company's drug candidate.
Via
The Motley Fool
Takeda Posts Lower 1H Profit, Lifts FY22 Outlook
October 27, 2022
Via
Benzinga
Stocks That Hit 52-Week Lows On Wednesday
October 19, 2022
On Wednesday, 200 companies hit new 52-week lows.
Via
Benzinga
Takeda Seeks FDA Approval For Hereditary Angioedema Treatment For Younger Kids
October 05, 2022
Via
Benzinga
Takeda's Approved Blood Cancer Drug Hits Primary Goal In Newly-Diagnosed Patient Settings
November 17, 2022
Via
Benzinga
Phase 3 Trial of ICLUSIG® (ponatinib) Met Primary Endpoint in Newly-Diagnosed Ph+ ALL, a Setting with No Targeted Treatments Approved in the US
November 17, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
2 Beaten-Down Dividend Stocks That Haven't Been This Cheap In More Than a Decade
November 16, 2022
Is now the time to load up on these high-yielding investments?
Via
The Motley Fool
European Commission (EC) Approves LIVTENCITYTM▼ (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Infection And/or Disease That Are Refractory (With or Without Resistance) to One or More Prior Therapies
November 11, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Why Denali Therapeutics' Stock Rose 6.6% on Wednesday
November 02, 2022
The biopharmaceutical stock was actually up as much as 12.4% before falling a bit at the close.
Via
The Motley Fool
Takeda Delivers Strong FY2022 H1 Results and Raises Full-Year Forecast
October 27, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
7 Dividend Stocks to Sell Pronto Before a Painful Downturn
October 24, 2022
Investors may find many dividend stocks to sell, considering returns from the risk-free U.S. Treasury Bills often exceed their yield.
Via
InvestorPlace
CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?
October 20, 2022
Despite enthusiasm in some camps, the risk of potential cures clouds market projections.
Via
Investor's Business Daily
Takeda Enters Collaboration and Licensing Agreement with Zedira and Dr. Falk Pharma to Develop First-in-Class Celiac Disease Therapy
October 20, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Earnings Scheduled For October 27, 2022
October 27, 2022
Companies Reporting Before The Bell • Janus Henderson Gr (NYSE:JHG) is expected to report quarterly earnings at $0.48 per share on revenue of $494.27 million.
Via
Benzinga
3 High-Yielding Dividend Stocks Near Their 52-Week Lows
October 19, 2022
These stocks all pay far higher than the S&P 500 average dividend yield of 1.8%.
Via
The Motley Fool
Takeda Receives Positive CHMP Opinion Recommending Approval of Dengue Vaccine Candidate in EU and Dengue-Endemic Countries
October 14, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Scientists Are Studying Psychedelic Drug as a Possible Treatment for Alzheimer’s Disease
October 05, 2022
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – October 5, 2022 – A Toronto-based biotech firm is developing a new psychedelic medicine to cure Alzheimer’s disease,...
Via
FinancialNewsMedia
Topics
Cannabis
Exposures
Cannabis
U.S. Food and Drug Administration Accepts Takeda’s Supplemental Biologics License Application for Use of TAKHZYRO® (lanadelumab-flyo) to Prevent Hereditary Angioedema (HAE) Attacks in Children 2 Years of Age and Older
October 05, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Strengthening Healthcare Systems to Meet Patients’ Need for Plasma-Derived Therapies
September 29, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung Cancer
September 21, 2022
Via
Benzinga
Takeda Signs Virtual Power Purchase Agreement with Enel North America to Advance Renewable Energy Production in the United States
September 19, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Receives Positive CHMP Opinion for Maribavir for the Treatment of Adults with Post-transplant Cytomegalovirus (CMV) Refractory (With or Without Resistance) to Prior Therapies
September 16, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Intellia Therapeutics Looks To Repeat Its Landmark Success In CRISPR Gene Editing
September 16, 2022
Intellia tested its CRISPR approach in cardiomyopathy and hereditary angioedema.
Via
Investor's Business Daily
Takeda Selects New Partners for Global Corporate Social Responsibility (CSR) Program to Strengthen Health Systems in Low- and Middle-Income Countries
September 13, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
7 Stocks Under $15 to Buy and Hold Forever
September 01, 2022
For patient investors who are willing to absorb potential turbulence, these are the stocks under $15 to buy for the long haul.
Via
InvestorPlace
Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary
August 30, 2022
Via
Benzinga
Y-mAbs Gets Regulatory Approval In Israel For Neuroblastoma Candidate
August 30, 2022
The Israeli Ministry of Health has approved Y-mAbs Therapeutics’ (NASDAQ: YMAB) lead drug DANYELZA in combination with granulocyte-macrophage colony-stimulating factor for pediatric patients 1 year of...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.